Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program.
Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169.
Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to obesity reduction.
Issues related to Alzheimers coverage and access.
Issues related to PBM reform.
Issues related to tax legislation; Tax Relief for American Families and Workers Act of 2024, H.R.7024.
Duration: April 1, 2017
to
present
General Issues: Pharmacy , Taxation/Internal Revenue Code , Medicare/Medicaid , Budget/Appropriations
Spending: about $1,680,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on April 22.
Original Filing: 301570348.xml
Lobbying Issues
Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program.
Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169.
Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to obesity reduction.
Issues related to Alzheimers coverage and access.
Issues related to PBM reform.
Lobbying Issues
Issues related to tax legislation; Tax Relief for American Families and Workers Act of 2024, H.R.7024.
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Jan. 22.
Original Filing: 301537127.xml
Lobbying Issues
Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program.
Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169.
Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to obesity reduction.
Issues related to Alzheimers coverage and access.
3rd Quarter, 2023
In Q3, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301513846.xml
Lobbying Issues
Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program.
Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169.
Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to obesity reduction.
Issues related to Alzheimers coverage and access.
2nd Quarter, 2023
In Q2, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on July 20, 2023.
Original Filing: 301489321.xml
Lobbying Issues
Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program.
Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169.
Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to obesity reduction.
Issues related to Alzheimers coverage and access.
1st Quarter, 2023
In Q1, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on April 20, 2023.
Original Filing: 301460373.xml
Lobbying Issues
Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program.
Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169.
Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to obesity reduction.
4th Quarter, 2022
In Q4, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Jan. 20, 2023.
Original Filing: 301441489.xml
Lobbying Issues
Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program.
Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169.
Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to CMS National Coverage Determination.
Issues related to the Treat and Reduce Obesity Act, S.596.
3rd Quarter, 2022
In Q3, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301412941.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy.
Monitoring healthcare, insulin, and drug pricing discussions related to the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169.
Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to CMS National Coverage Determination.
2nd Quarter, 2022
In Q2, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301395063.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy.
Monitoring healthcare and drug pricing discussions related to the Budget Reconciliation Package, H.R.5376.
Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to CMS National Coverage Determination.
1st Quarter, 2022
In Q1, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301365328.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy.
Monitoring healthcare discussions related to the Budget Reconciliation Package, Build Back Better Act, H.R.5376.
Monitoring discussions related to the infrastructure package, Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
Issues related to CMS National Coverage Determination.
4th Quarter, 2021
In Q4, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301332042.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy.
Monitoring healthcare discussions related to the Budget Reconciliation Package, Build Back Better Act, H.R.5376.
Monitoring discussions related to the infrastructure package, Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58.
3rd Quarter, 2021
In Q3, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Oct. 20, 2021.
Original Filing: 301309507.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy.
Monitoring healthcare discussions related to the Budget Reconciliation Package, Build Back Better Act, H.R.5376.
Monitoring discussions related to the infrastructure package, Infrastructure Investment and Jobs Act, H.R.3684.
2nd Quarter, 2021
In Q2, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301289049.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy.
Monitoring healthcare issues related to the American Rescue Plan Act of 2021, H.R.1319, P.L.117-2.
Monitoring discussions related to an infrastructure package.
1st Quarter, 2021
In Q1, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301260922.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy.
Monitoring healthcare issues related to the American Rescue Plan Act of 2021, H.R.1319, P.L.117-2.
4th Quarter, 2020
In Q4, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Jan. 20, 2021.
Original Filing: 301239814.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy and cost; Lower Health Care Costs Act of 2019, S.1895.
Healthcare issues related to the CARES Act, H.R.748, P.L.116-136 implementation and additional COVID-19 legislative proposals, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes, H.R.133, P.L.116-260.
Lobbying Issues
Issues related to the implementation of the Tax Cuts and Jobs Act, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D coverage and reimbursement policies.
Issues related to Medicaid reimbursement.
Issues related to drug pricing; Prescription Drug Pricing Reduction Act of 2019, S.2543.
3rd Quarter, 2020
In Q3, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Oct. 20, 2020.
Original Filing: 301223370.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy and cost; Lower Health Care Costs Act of 2019, S.1895.
Healthcare issues related to the CARES Act, H.R.748, P.L.116-136 implementation and additional COVID-19 legislative proposals.
Lobbying Issues
Issues related to the implementation of the Tax Cuts and Jobs Act, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D coverage and reimbursement policies.
Issues related to Medicaid reimbursement.
Issues related to drug pricing; Prescription Drug Pricing Reduction Act of 2019, S.2543.
2nd Quarter, 2020
In Q2, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301198054.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy and cost; Lower Health Care Costs Act of 2019, S.1895.
Healthcare issues related to the CARES Act, H.R.748, P.L.116-136 implementation and additional COVID-19 legislative proposals.
Lobbying Issues
Issues related to the implementation of the Tax Cuts and Jobs Act, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D coverage and reimbursement policies.
Issues related to Medicaid reimbursement.
Issues related to drug pricing; Prescription Drug Pricing Reduction Act of 2019, S.2543.
1st Quarter, 2020
In Q1, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301174095.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy and cost; Lower Health Care Costs Act of 2019, S.1895.
Healthcare issues related to the CARES Act, H.R.748, P.L.116-136.
Lobbying Issues
Issues related to the implementation of the Tax Cuts and Jobs Act, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D coverage and reimbursement policies.
Issues related to Medicaid reimbursement.
Issues related to drug pricing; Prescription Drug Pricing Reduction Act of 2019, S.2543.
4th Quarter, 2019
In Q4, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128170.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy and cost; Lower Health Care Costs Act of 2019, S.1895.
Lobbying Issues
Issues related to the implementation of the Tax Cuts and Jobs Act, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D coverage and reimbursement policies.
Issues related to Medicaid reimbursement.
Issues related to drug pricing; Prescription Drug Pricing Reduction Act of 2019, S.2543.
Lobbying Issues
Monitoring healthcare issues related to the Further Consolidated Appropriations Act, 2020, H.R.1865, P.L.116-94.
3rd Quarter, 2019
In Q3, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301075297.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy and cost; Lower Health Care Costs Act of 2019, S.1895.
Lobbying Issues
Issues related to the implementation of the Tax Cuts and Jobs Act, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D coverage and reimbursement policies.
Issues related to Medicaid reimbursement.
Issues related to drug pricing; Prescription Drug Pricing Reduction Act of 2019, S.2543.
Lobbying Issues
Monitoring issues related to the Bipartisan Budget Act of 2019, H.R.3877, P.L.116-37 and the Continuing Appropriations Act, 2020, and Health Extenders Act of 2019, H.R.4378, P.L.116-59.
2nd Quarter, 2019
In Q2, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301056193.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to healthcare policy and cost; Lower Health Care Costs Act of 2019, S.1895.
Lobbying Issues
Issues related to the implementation of the Tax Cuts and Jobs Act, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D coverage and reimbursement policies.
Issues related to Medicaid reimbursement.
1st Quarter, 2019
In Q1, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on April 22, 2019.
Original Filing: 301036963.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Lobbying Issues
Issues related to the implementation of the Tax Cuts and Jobs Act, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Part D coverage and reimbursement policies.
4th Quarter, 2018
In Q4, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301014831.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Lobbying Issues
Issues related to the implementation of Tax Cuts and Jobs Act, H.R.1, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Part D coverage and reimbursement policies.
3rd Quarter, 2018
In Q3, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Oct. 22, 2018.
Original Filing: 300997183.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Issues related to the Hatch-Waxman Integrity Act of 2018.
Lobbying Issues
Issues related to the implementation of Tax Cuts and Jobs Act, H.R.1, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Part D coverage and reimbursement policies.
2nd Quarter, 2018
In Q2, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300974344.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing, drug value, and the 340B Program.
Lobbying Issues
Issues related to the implementation of Tax Cuts and Jobs Act, H.R.1, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Part D coverage and reimbursement policies.
1st Quarter, 2018
In Q1, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300956762.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing and value, the 340B Program and IPAB repeal.
Lobbying Issues
Issues related to tax reform; implementation of Tax Cuts and Jobs Act, H.R.1, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Part D coverage and reimbursement policies; Making further continuing appropriations for the fiscal year ending September 30, 2018, and for other purposes, H.R.195, P.L.115-120; Bipartisan Budget Act of 2018, H.R.1892, P.L.115-123; Consolidated Appropriations Act, 2018, H.R.1625, P.L.115-141.
4th Quarter, 2017
In Q4, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Jan. 22, 2018.
Original Filing: 300933148.xml
Lobbying Issues
Issues related to the pharmaceutical industry including drug pricing and value, the 340B Program and IPAB repeal.
Lobbying Issues
Issues related to tax reform; Tax Cuts and Jobs Act, H.R.1, P.L.115-97.
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on Oct. 20, 2017.
Original Filing: 300911800.xml
Lobbying Issues
Monitoring pharmaceutical issues in the American Health Care Act of 2017, H.R.1628 and Better Care Reconciliation Act of 2017.
Monitoring pharmaceutical issues in the FDA Reauthorization Act of 2017, P.L.115-52.
Issues related to drug pricing and value.
Lobbying Issues
Issues related to tax reform.
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, The Simmons & Russell Group, LLC lobbied for Eli Lilly and Company , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300895349.xml
Lobbying Issues
Monitoring pharmaceutical issues in the Better Care Reconciliation Act of 2017.
Monitoring pharmaceutical issues in the FDA Reauthorization Act of 2017, S.934.
Issues related to drug pricing and value.
2nd Quarter, 2017
The Simmons & Russell Group, LLC filed a lobbying registration on May 3, 2017 to represent Eli Lilly and Company, effective April 1, 2017.
Original Filing: 300879619.xml
Issue(s) they said they’d lobby about: Legislative and regulatory issues affecting the pharmaceutical industry. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...